BioCentury
ARTICLE | Clinical News

Alisertib: Development discontinued

May 18, 2015 7:00 AM UTC

Takeda discontinued development of alisertib to treat relapsed or refractory PTCL after a pre-specified interim analysis of an open-label, international Phase III trial showed that twice-daily oral al...